COVID-19
Conditions
Keywords
sars-cov-2, coronavirus, vaccine, adjuvant, Advax, Spikogen, Covax-19
Brief summary
This study will determine the immunogenicity of Spikogen in vaccine naïve individuals. Spikogen will be administered as two doses 1 month apart with a third booster dose either 1 or 3 months after the second dose. This study will provide key data on SARS-CoV-2 antibody responses.
Detailed description
The SARS-CoV-2 outbreak has caused millions of deaths globally. It has a particularly high mortality rate in elderly people and those with chronic disease where mortality rates can be as high as 20-30%. SARS-COV-2 vaccines remain a key priority to help fight the current pandemic. COVID-19 vaccines prevent symptomatic infection and may help reduce virus transmission. Spikogen® vaccine, also known as Covax-19™ in Australia, is an adjuvanted recombinant protein Covid-19 vaccine has recently been approved by the Iranian FDA for emergency use in Iran in adults as a primary vaccine course and booster dose, after meeting its primary efficacy endpoint in a Phase 3 trial in 16,876 participants randomised 3:1 to receive Spikogen vaccine or saline placebo via two intramuscular doses 3 weeks apart where Spikogen vaccine demonstrated significant protection against serious infection with the delta variant. Approximately 5-10% of the broader Australian population and an even higher proportion of the indigenous populations remains unvaccinated despite current availability of these vaccines. One reason is that some people have medical contraindications to the current vaccines, such as serious allergies to the vaccine components such as polyethyleneglycol (PEG) in the mRNA vaccines. Spikogen vaccine is made using a recombinant protein approach with the SARS-CoV-2 spike protein synthesized in an insect cell line grown in broth. Insect cell expression of recombinant protein is a well-established vaccine manufacturing approach. Spikogen vaccine also contains a unique Australian developed adjuvant called Advax-CpG55.2, which is added to the spike protein to make the vaccine more effective. AdvaxCpG55.2 has two components, one a natural plant sugar called inulin, and the second a short synthetic oligonucleotide polymer, known as CpG55.2 oligonucleotide. Spikogen vaccine is designed to protect against SARS-CoV-2 infection. It has been shown to be effective against infection in hamster, ferret and monkey SARS-CoV-2 infection models. This study will determine the immunogenicity of Spikogen in vaccine-naïve individuals. Spikogen will be administered as two doses 31 month apart with a third booster dose given either 1 or 3 months after the second dose.
Interventions
BIOLOGICALAdvax-CpG55.2 adjuvanted recombinant spike protein
recombinant SARS-CoV-2 spike protein formulated with Advax-CpG55.2 adjuvant
Sponsors
Australian Respiratory and Sleep Medicine Institute
Vaxine Pty Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
Subjects will be stratified for analysis by age, sex and seropositivity at time of study entry
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Able to provide written informed consent * Males or females\* 18 years of age or older * Understand and are likely to comply with planned study procedures and be available for all study visits. * Have not previously had a Covid-19 vaccine and do not intend to have a non-study Covid-19 vaccine within the next 6 months
Exclusion criteria
* History of Covid-19 vaccination. * History of serious vaccine allergy. * Pregnancy1 * Have received an experimental agent within 30 days prior to the study vaccination or expect to receive another experimental agent during the trial reporting period. * Any medical, social or mental condition which, in the opinion of the investigator, would be detrimental to the subjects or the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serious adverse events (SAE) | through study completion, an average of 7 months | Number of Serious adverse events (SAE) occurring within study period in each group stratified by baseline antibody positivity |
| First dose Seroconversion | 2-4 weeks post first immunisation | Proportion of subjects in each group stratified by baseline antibody positivity seroconverting to spike protein antibody positivity |
| Second dose Seroconversion | 2-4 weeks post second immunisation | Proportion of subjects in each group stratified by baseline antibody positivity seroconverting to spike protein antibody positivity |
| Third Dose Seroconversion | 2-4 weeks post third immunisation | Proportion of subjects in each group stratified by baseline antibody positivity seroconverting to spike protein antibody positivity |
| Final Seroconversion | through study completion, an average of 7 months | Proportion of subjects in each group stratified by baseline antibody positivity seroconverting to spike protein antibody positivity |
| First Dose GMT | 2-4 weeks post first immunisation | Spike protein antibody Geometric Mean Titers (GMT) in each group stratified by baseline antibody positivity |
| Second Dose GMT | 2-4 weeks post second immunisation | Spike protein antibody Geometric Mean Titers (GMT) in each group stratified by baseline antibody positivity |
| Third Dose GMT | 2-4 weeks post third immunisation | Spike protein antibody Geometric Mean Titers (GMT)in each group stratified by baseline antibody positivity |
| Final GMT | through study completion, an average of 7 months | Spike protein antibody Geometric Mean Titers (GMT)in each group stratified by baseline antibody positivity |
| First Dose Adverse events (AE) | 7 days post first immunisation | AE occurring within 7 days of immunisation in each group stratified by baseline antibody positivity |
| Second Dose Adverse events (AE) | 7 days post second immunisation | AE occurring within 7 days of immunisation in each group stratified by baseline antibody positivity |
| Third Dose Adverse events (AE) | 7 days post third immunisation | AE occurring within 7 days of immunisation in each group stratified by baseline antibody positivity |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Third dose Vaccine efficacy | From 2 weeks post-third dose through study completion, an average of 7 months | Proportion of Covid-19 infections in trial participants in each group stratified by baseline antibody positivity |
| Total Covid-19 infections | From first vaccine dose through study completion, an average of 7 months | Proportion of breakthrough Covid-19 infections in trial participants in each group stratified by baseline antibody positivity |
| Seroconversion against variants of concern | 2-4 weeks post first, second and third immunisation and at study completion | Serum spike protein antibody seroconversion rates against each SARS-CoV-2 variant of concern in trial participants in each group stratified by baseline antibody positivity |
| GMT against variants of concern | 2-4 weeks post first, second and third immunisation and at study completion | Geometric mean serum spike protein antibodies against SARS-CoV-2 variants in trial participants in each group stratified by baseline antibody positivity |
| First dose Vaccine efficacy | From 2 weeks post-first dose to 2 weeks after second dose | Proportion of Covid-19 infections in trial participants in each group stratified by baseline antibody positivity |
| Second dose Vaccine efficacy | From 2 weeks post-second dose to 2 weeks after third dose | Proportion of Covid-19 infections in trial participants in each group stratified by baseline antibody positivity |
Other
| Measure | Time frame | Description |
|---|---|---|
| Antibody kinetics | 2-4 weeks post first, second and third immunisation and at study completion | rate of change in peak to trough serum spike protein antibody levels over time in each group stratified by baseline antibody positivity |
| Age effects on antibody levels | 2-4 weeks post first, second and third immunisation and at study completion | Geometric Mean Titers of spike protein antibodies in participants by age and gender |
| immune-deficiency effects on seroconversion | 2-4 weeks post first, second and third immunisation and at study completion | Proportion of subjects seroconverting to spike protein antibodies in participants with or without immune-deficiency |
| immune-deficiency effects on antibody levels | 2-4 weeks post first, second and third immunisation and at study completion | Geometric Mean Titers (GMT) of spike protein antibodies in participants with or without immune-deficiency |
| Age effects on seroconversion | 2-4 weeks post first, second and third immunisation and at study completion | Proprotion seroconverting to spike protein antibodies analysed by age and gender |
Countries
Australia
Outcome results
None listed